EFS for patients with KMT2A-r acute myeloid leukemia. EFS from study entry for the entire study cohort (n = 215) and by specific translocation partners associated with higher-risk KMT2A-r AML (n = 70), non–high-risk KMT2A-r AML (n = 107), and other KMT2A-r subsets (n = 28). AML, acute myeloid leukemia; EFS, event-free survival; KMT2A-r, KMT2A-rearranged.